Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).

NCT01581593 is registered in ClinicalTrials.gov with Kedrion S.p.A. as lead sponsor.

NCT NCT01581593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01581593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).
Lead sponsor
Kedrion S.p.A.
Phase
Phase 3
Overall status
Completed
Start date
November 12, 2012
Completion date
August 27, 2014
Enrollment
45 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

agammaglobulinemia, antibody deficiency, hypogammaglobulinemia, primary immunodeficiency